{"id":648860,"date":"2017-04-13T03:58:48","date_gmt":"2017-04-13T03:58:48","guid":{"rendered":"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/"},"modified":"2017-04-13T03:58:48","modified_gmt":"2017-04-13T03:58:48","slug":"why-big-pharma-is-turning-to-biological-meds","status":"publish","type":"post","link":"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/","title":{"rendered":"Why big pharma is turning to biological meds"},"content":{"rendered":"

Why big pharma is turning to biological meds: <\/strong>Biological meds are increasingly being seen as more lucrative to pharma companies than the standard chemical kinds. While chemical drugs are based on small, stable molecules (and have been used since the industry emerged), their biological counterparts are based on much larger and more volatile proteins. Despite their lack of stability, biologics-based drugs have recently become more appealing to big pharma companies as they use our own DNA to cure us, making them more effective than chemical meds in treating genetic diseases such as diabetes and cancer, the Wall Street Journal\u2019s Preetika Rana explains<\/a> (runtime 2:53).<\/p>\n","protected":false},"excerpt":{"rendered":"

Why big pharma is turning to biological meds: Biological meds are increasingly being seen as more lucrative to pharma companies than the standard chemical kinds. While chemical drugs are based on small, stable molecules (and have been used since the industry emerged), their biological counterparts are based on much larger and more volatile proteins. Despite […]<\/p>\n","protected":false},"author":1,"featured_media":648861,"comment_status":"closed","ping_status":"open","sticky":false,"template":"single-feature.php","format":"standard","meta":{"_acf_changed":false,"newspack_ads_suppress_ads":false,"newspack_popups_has_disabled_popups":false,"newspack_sponsor_sponsorship_scope":"","newspack_sponsor_native_byline_display":"inherit","newspack_sponsor_native_category_display":"inherit","newspack_sponsor_underwriter_style":"inherit","newspack_sponsor_underwriter_placement":"inherit","ep_exclude_from_search":false,"_primary_brand":0,"newspack_featured_image_position":"","newspack_post_subtitle":"","newspack_article_summary_title":"Overview:","newspack_article_summary":"","newspack_hide_updated_date":false,"newspack_show_updated_date":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[9004],"tags":[72,2388],"brand":[],"newspack_spnsrs_tax":[],"class_list":["post-648860","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-worth-watching","tag-enterpriseam","tag-worth-watching","wpautop","entry"],"acf":{"mongo_id":"d9733d62-4ad1-4173-92b2-54c4b5a92aa8","order":"0","is_powered_by":true,"story_type":"1","photo_url":"https:\/\/ent.news\/2017\/4\/2285.jpg","photo_position":"above","related_issue":[648834],"teaser":"","voice_url":""},"yoast_head":"\nWhy big pharma is turning to biological meds - EnterpriseAM Egypt<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Why big pharma is turning to biological meds\" \/>\n<meta property=\"og:description\" content=\"Why big pharma is turning to biological meds: Biological meds are increasingly being seen as more lucrative to pharma companies than the standard chemical kinds. While chemical drugs are based on small, stable molecules (and have been used since the industry emerged), their biological counterparts are based on much larger and more volatile proteins. Despite […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/\" \/>\n<meta property=\"og:site_name\" content=\"EnterpriseAM Egypt\" \/>\n<meta property=\"article:published_time\" content=\"2017-04-13T03:58:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/ent.news\/2017\/4\/2285.jpg?fit=%2C&ssl=1\" \/>\n<meta name=\"author\" content=\"enterpriseam admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"enterpriseam admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/\"},\"author\":{\"name\":\"enterpriseam admin\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#\/schema\/person\/ca597032db7e4db868359c123cec256d\"},\"headline\":\"Why big pharma is turning to biological meds\",\"datePublished\":\"2017-04-13T03:58:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/\"},\"wordCount\":112,\"publisher\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#organization\"},\"image\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/ent.news\/2017\/4\/2285.jpg?fit=%2C&ssl=1\",\"keywords\":[\"EnterpriseAM\",\"worth watching\"],\"articleSection\":[\"Worth watching\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/\",\"url\":\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/\",\"name\":\"Why big pharma is turning to biological meds - EnterpriseAM Egypt\",\"isPartOf\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/ent.news\/2017\/4\/2285.jpg?fit=%2C&ssl=1\",\"datePublished\":\"2017-04-13T03:58:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/#primaryimage\",\"url\":\"https:\/\/i0.wp.com\/ent.news\/2017\/4\/2285.jpg?fit=%2C&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/ent.news\/2017\/4\/2285.jpg?fit=%2C&ssl=1\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/enterpriseam.com\/egypt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Why big pharma is turning to biological meds\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#website\",\"url\":\"https:\/\/enterpriseam.com\/egypt\/\",\"name\":\"EnterpriseAM\",\"description\":\"The State of the Nation\",\"publisher\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/enterpriseam.com\/egypt\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#organization\",\"name\":\"EnterpriseAM\",\"url\":\"https:\/\/enterpriseam.com\/egypt\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ent.news\/internal\/240894.svg\",\"contentUrl\":\"https:\/\/ent.news\/internal\/240894.svg\",\"caption\":\"EnterpriseAM\"},\"image\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#\/schema\/person\/ca597032db7e4db868359c123cec256d\",\"name\":\"enterpriseam admin\",\"sameAs\":[\"http:\/\/enterpriseam.testing.projectsarea.com\"],\"url\":\"https:\/\/enterpriseam.com\/egypt\/author\/enterpriseam\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Why big pharma is turning to biological meds - EnterpriseAM Egypt","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/","og_locale":"en_US","og_type":"article","og_title":"Why big pharma is turning to biological meds","og_description":"Why big pharma is turning to biological meds: Biological meds are increasingly being seen as more lucrative to pharma companies than the standard chemical kinds. While chemical drugs are based on small, stable molecules (and have been used since the industry emerged), their biological counterparts are based on much larger and more volatile proteins. Despite […]","og_url":"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/","og_site_name":"EnterpriseAM Egypt","article_published_time":"2017-04-13T03:58:48+00:00","og_image":[{"url":"https:\/\/i0.wp.com\/ent.news\/2017\/4\/2285.jpg?fit=%2C&ssl=1","type":"","width":"","height":""}],"author":"enterpriseam admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"enterpriseam admin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/#article","isPartOf":{"@id":"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/"},"author":{"name":"enterpriseam admin","@id":"https:\/\/enterpriseam.com\/egypt\/#\/schema\/person\/ca597032db7e4db868359c123cec256d"},"headline":"Why big pharma is turning to biological meds","datePublished":"2017-04-13T03:58:48+00:00","mainEntityOfPage":{"@id":"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/"},"wordCount":112,"publisher":{"@id":"https:\/\/enterpriseam.com\/egypt\/#organization"},"image":{"@id":"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/ent.news\/2017\/4\/2285.jpg?fit=%2C&ssl=1","keywords":["EnterpriseAM","worth watching"],"articleSection":["Worth watching"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/","url":"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/","name":"Why big pharma is turning to biological meds - EnterpriseAM Egypt","isPartOf":{"@id":"https:\/\/enterpriseam.com\/egypt\/#website"},"primaryImageOfPage":{"@id":"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/#primaryimage"},"image":{"@id":"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/ent.news\/2017\/4\/2285.jpg?fit=%2C&ssl=1","datePublished":"2017-04-13T03:58:48+00:00","breadcrumb":{"@id":"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/#primaryimage","url":"https:\/\/i0.wp.com\/ent.news\/2017\/4\/2285.jpg?fit=%2C&ssl=1","contentUrl":"https:\/\/i0.wp.com\/ent.news\/2017\/4\/2285.jpg?fit=%2C&ssl=1"},{"@type":"BreadcrumbList","@id":"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/enterpriseam.com\/egypt\/"},{"@type":"ListItem","position":2,"name":"Why big pharma is turning to biological meds"}]},{"@type":"WebSite","@id":"https:\/\/enterpriseam.com\/egypt\/#website","url":"https:\/\/enterpriseam.com\/egypt\/","name":"EnterpriseAM","description":"The State of the Nation","publisher":{"@id":"https:\/\/enterpriseam.com\/egypt\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/enterpriseam.com\/egypt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/enterpriseam.com\/egypt\/#organization","name":"EnterpriseAM","url":"https:\/\/enterpriseam.com\/egypt\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/enterpriseam.com\/egypt\/#\/schema\/logo\/image\/","url":"https:\/\/ent.news\/internal\/240894.svg","contentUrl":"https:\/\/ent.news\/internal\/240894.svg","caption":"EnterpriseAM"},"image":{"@id":"https:\/\/enterpriseam.com\/egypt\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/enterpriseam.com\/egypt\/#\/schema\/person\/ca597032db7e4db868359c123cec256d","name":"enterpriseam admin","sameAs":["http:\/\/enterpriseam.testing.projectsarea.com"],"url":"https:\/\/enterpriseam.com\/egypt\/author\/enterpriseam\/"}]}},"featured_image_src":"https:\/\/i0.wp.com\/ent.news\/2017\/4\/2285.jpg?resize=600%2C400&ssl=1","featured_image_src_square":"https:\/\/i0.wp.com\/ent.news\/2017\/4\/2285.jpg?resize=600%2C600&ssl=1","author_info":{"display_name":"enterpriseam admin","author_link":"https:\/\/enterpriseam.com\/egypt\/author\/enterpriseam\/"},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/ent.news\/2017\/4\/2285.jpg?fit=%2C&ssl=1","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":588378,"url":"https:\/\/enterpriseam.com\/egypt\/2023\/06\/11\/roche-partners-with-eva-pharma-to-produce-meds-for-organ-transplant-patients\/","url_meta":{"origin":648860,"position":0},"title":"Roche partners with Eva Pharma to produce meds for organ transplant patients","author":"enterpriseam admin","date":"11 June 2023","format":false,"excerpt":"Organ transplant patients will soon have access to locally produced meds","rel":"","context":"In "Manufacturing"","block_context":{"text":"Manufacturing","link":"https:\/\/enterpriseam.com\/egypt\/category\/industries\/manufacturing\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/ent.news\/2023\/6\/473.jpg?fit=%2C&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":560270,"url":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/22\/ibnsina-to-distribute-bayer-meds-in-egypt-rameda-looks-to-invest\/","url_meta":{"origin":648860,"position":1},"title":"Ibnsina to distribute Bayer meds in Egypt, Rameda looks to invest","author":"enterpriseam admin","date":"22 February 2021","format":false,"excerpt":"Ibnsina Pharma has signed an agreement with Germany\u2019s Bayer to import and distribute products from its OTC and Rx-based portfolios, the companies said in a joint statement (pdf) today. Bayer wants to grow in Egypt: Bayer Consumer Health wants to increase sales by 30% in 2021 after recording sales of\u2026","rel":"","context":"In "PHARMA"","block_context":{"text":"PHARMA","link":"https:\/\/enterpriseam.com\/egypt\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/ent.news\/2021\/2\/314.jpg?fit=%2C&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":570572,"url":"https:\/\/enterpriseam.com\/egypt\/2020\/04\/06\/novo-nordisk-to-offer-four-new-meds-in-egypt\/","url_meta":{"origin":648860,"position":2},"title":"Novo Nordisk to offer four new meds in Egypt","author":"enterpriseam admin","date":"6 April 2020","format":false,"excerpt":"Danish pharma giant Novo Nordisk is in the process of registering four new meds in Egypt to introduce them by 2022, the company\u2019s deputy chairman in Egypt Ayman Hassan told the local press, without providing further details on the products.","rel":"","context":"In "Health + Education"","block_context":{"text":"Health + Education","link":"https:\/\/enterpriseam.com\/egypt\/category\/health-education\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/ent.news\/internal\/536550.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":588632,"url":"https:\/\/enterpriseam.com\/egypt\/2023\/06\/14\/eva-pharma-plans-usd-110-mn-saudi-meds-complex\/","url_meta":{"origin":648860,"position":3},"title":"Eva Pharma plans USD 110 mn Saudi meds complex","author":"enterpriseam admin","date":"14 June 2023","format":false,"excerpt":"The company wants to build five factories and a research hub","rel":"","context":"In "Also on our Radar"","block_context":{"text":"Also on our Radar","link":"https:\/\/enterpriseam.com\/egypt\/category\/also-on-our-radar\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/ent.news\/2023\/6\/691.jpg?fit=%2C&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":639664,"url":"https:\/\/enterpriseam.com\/egypt\/2024\/08\/13\/govt-to-end-meds-shortage-with-subsidized-loans-for-pharma-players\/","url_meta":{"origin":648860,"position":4},"title":"Gov\u2019t to end meds shortage with subsidized loans for pharma players","author":"enterpriseam admin","date":"13 August 2024","format":false,"excerpt":"Drug prices will soon see hikes ranging between 10-50%","rel":"","context":"In "PHARMA"","block_context":{"text":"PHARMA","link":"https:\/\/enterpriseam.com\/egypt\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/ent.news\/2024\/8\/1023.jpg?fit=%2C&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":593420,"url":"https:\/\/enterpriseam.com\/egypt\/2019\/11\/27\/efg-led-rx-healthcare-confirms-closing-egyptian-meds-producer-united-pharma-acquisition\/","url_meta":{"origin":648860,"position":5},"title":"EFG-led Rx Healthcare confirms closing Egyptian meds producer United Pharma acquisition","author":"enterpriseam admin","date":"27 November 2019","format":false,"excerpt":"M&A WATCH- Rx Healthcare confirms closing United Pharma acquisition: EFG Hermes\u2019 Rx Healthcare Fund has confirmed media reportst that it has acquired a majority stake in meds producer United Pharma, according to an emailed statement (pdf). Rx carried out the acquisition through Nutritius Investment Holdings, a special purpose vehicle established\u2026","rel":"","context":"In "Speed Round"","block_context":{"text":"Speed Round","link":"https:\/\/enterpriseam.com\/egypt\/category\/speed-round\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/ent.news\/internal\/536550.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]}],"_links":{"self":[{"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/posts\/648860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/comments?post=648860"}],"version-history":[{"count":0,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/posts\/648860\/revisions"}],"acf:post":[{"embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/issue\/648834"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/media\/648861"}],"wp:attachment":[{"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/media?parent=648860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/categories?post=648860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/tags?post=648860"},{"taxonomy":"brand","embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/brand?post=648860"},{"taxonomy":"newspack_spnsrs_tax","embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/newspack_spnsrs_tax?post=648860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}